SCHEMBL2010793

SCHEMBL2010793

Nc1nc(C2O[C@H](CO)[C@H](O)[C@H]2O)nc2nc[nH]c12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.43
GDA Q9Y2T3 1/20 0.43
HIF1A Q16665 3/20 0.40
PYGL P06737 4/20 0.37
KDM4E B2RXH2 1/20 0.37
GMNN O75496 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
NFKB1 P19838 1/20 0.37
STAT6 P42226 1/20 0.37
KDR P35968 1/20 0.37
AURKB Q96GD4 1/20 0.37
PNP P00491 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7752119 1.00 PDPK1 (0.43) PDPK1GDAHIF1APYGLKDM4E
SCHEMBL2636634 1.00 PDPK1 (0.43) PDPK1GDAHIF1APYGLKDM4E
SCHEMBL5182602 1.00 PDPK1 (0.43) PDPK1GDAHIF1APYGLKDM4E
SCHEMBL8331267 1.00 PDPK1 (0.43) PDPK1GDAHIF1APYGLKDM4E
SCHEMBL4436406 1.00 PDPK1 (0.43) PDPK1GDAHIF1APYGLKDM4E
SCHEMBL9393271 1.00 PDPK1 (0.43) PDPK1GDAHIF1APYGLKDM4E
SCHEMBL1994118 1.00 PDPK1 (0.43) PDPK1GDAHIF1APYGLKDM4E
SCHEMBL240029 1.00 PDPK1 (0.43) PDPK1GDAHIF1APYGLKDM4E
SCHEMBL8509311 1.00 PDPK1 (0.43) PDPK1GDAHIF1APYGLKDM4E
SCHEMBL31624452 1.00 PDPK1 (0.43) PDPK1GDAHIF1APYGLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004096138-A2 [18F]-FURANOSYLPURINE DERIVATIVES AND USES THEREOF UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2004-11-11 WO claimed
US-20030068631-A1 Method for the identification of synthetic cell-or tissue-specific transcriptional regulatory regions BAYLOR COLLEGE OF MEDICINE 2003-04-10 US claimed
US-6410228-B1 DETERMINATING BINDING SITES BAYLOR COLLEGE OF MEDICINE 2002-06-25 US claimed
EP-1003911-A1 METHOD FOR THE IDENTIFICATION OF SYNTHETIC CELL- OR TISSUE-SPECIFIC TRANSCRIPTIONAL REGULATORY REGIONS Valentis Inc. (US) 2000-05-31 EP claimed
WO-1999002737-A1 METHOD FOR THE IDENTIFICATION OF SYNTHETIC CELL- OR TISSUE-SPECIFIC TRANSCRIPTIONAL REGULATORY REGIONS VALENTIS, INC. (US) 1999-01-21 WO claimed
WO-2011119901-A1 GENE AMPLIFICATION AND TRANSFECTION METHODS AND REAGENTS RELATED THERETO ALNYLAM PHARMACEUTICALS, INC. (US) 2011-09-29 WO disclosed
US-7960536-B2 Artificially generated promoter sequences for use in monitoring transcription factor binding; gene expression regulation GENETRONICS, INC. (US) 2011-06-14 US disclosed
US-7749720-B2 Methods of identifying compounds for producing insulin sensitization THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-07-06 US disclosed
EP-1963366-A4 METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION PROMEGA CORP (US) 2009-05-06 EP disclosed
US-20080227738-A1 Compositions and methods for cell dedifferentiation and tissue regeneration UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2008-09-18 US disclosed
EP-1963366-A2 METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION PROMEGA CORPORATION (US) 2008-09-03 EP disclosed
US-20080206252-A1 Novel Polypeptides, and Nucleic Acids Encoding the Same GENENTECH, INC. (US) 2008-08-28 US disclosed
WO-1993008296-A1 OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES ISIS PHARMACEUTICALS, INC. (US) 1993-04-29 WO disclosed
WO-1993007281-A1 METHOD FOR GENETICALLY MODIFYING BONE MARROW CELLS OF PRIMATES, AND USEFUL CELLS THEREFOR THAT PRODUCE RECOMBINANT RETROVIRAL VECTORS NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 1993-04-15 WO disclosed
WO-1992007080-A1 A EUKARYOTIC EPISOMAL DNA CLONING AND EXPRESSION VECTOR BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1992-04-30 WO disclosed
US-4997926-A Viricides SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1991-03-05 US disclosed
EP-0355135-A4 ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES. SCRIPPS CLINIC RES (US) 1990-04-09 EP disclosed
EP-0355135-A1 ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1990-02-28 EP disclosed
EP-0319206-A2 Gene amplification BERLEX LABORATORIES, INC. (US) 1989-06-07 EP disclosed
WO-1989004662-A1 ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080206252-A1 Novel Polypeptides, and Nucleic Acids Encoding the Same DDX21, PABPC4, UPF1 PDPK1 4254/4885GDA 861/4885HIF1A 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.